Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor

Thomas A. Hope, Miguel Hernandez Pampaloni, Eric Nakakura, Henry VanBrocklin, James Slater, Salma Jivan, Carina Mari Aparici, Judy Yee, Emily Bergsland

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.

Original languageEnglish (US)
Pages (from-to)1432-1440
Number of pages9
JournalAbdominal Imaging
Volume40
Issue number6
DOIs
StatePublished - Aug 12 2015
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Liver
Contrast Media
Neoplasm Metastasis
gadolinium ethoxybenzyl DTPA
Positron Emission Tomography Computed Tomography

Keywords

  • Ga-68 DOTA-TOC
  • Hepatobiliary agents
  • Neuroendocrine tumor
  • PET/MRI

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

Hope, T. A., Pampaloni, M. H., Nakakura, E., VanBrocklin, H., Slater, J., Jivan, S., ... Bergsland, E. (2015). Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal Imaging, 40(6), 1432-1440. https://doi.org/10.1007/s00261-015-0409-9

Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. / Hope, Thomas A.; Pampaloni, Miguel Hernandez; Nakakura, Eric; VanBrocklin, Henry; Slater, James; Jivan, Salma; Aparici, Carina Mari; Yee, Judy; Bergsland, Emily.

In: Abdominal Imaging, Vol. 40, No. 6, 12.08.2015, p. 1432-1440.

Research output: Contribution to journalArticle

Hope, TA, Pampaloni, MH, Nakakura, E, VanBrocklin, H, Slater, J, Jivan, S, Aparici, CM, Yee, J & Bergsland, E 2015, 'Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor', Abdominal Imaging, vol. 40, no. 6, pp. 1432-1440. https://doi.org/10.1007/s00261-015-0409-9
Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S et al. Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdominal Imaging. 2015 Aug 12;40(6):1432-1440. https://doi.org/10.1007/s00261-015-0409-9
Hope, Thomas A. ; Pampaloni, Miguel Hernandez ; Nakakura, Eric ; VanBrocklin, Henry ; Slater, James ; Jivan, Salma ; Aparici, Carina Mari ; Yee, Judy ; Bergsland, Emily. / Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. In: Abdominal Imaging. 2015 ; Vol. 40, No. 6. pp. 1432-1440.
@article{3972a39a190b497db914377b827438bb,
title = "Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor",
abstract = "Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99{\%} vs. 46{\%} and 64{\%}, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.",
keywords = "Ga-68 DOTA-TOC, Hepatobiliary agents, Neuroendocrine tumor, PET/MRI",
author = "Hope, {Thomas A.} and Pampaloni, {Miguel Hernandez} and Eric Nakakura and Henry VanBrocklin and James Slater and Salma Jivan and Aparici, {Carina Mari} and Judy Yee and Emily Bergsland",
year = "2015",
month = "8",
day = "12",
doi = "10.1007/s00261-015-0409-9",
language = "English (US)",
volume = "40",
pages = "1432--1440",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Simultaneous 68Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor

AU - Hope, Thomas A.

AU - Pampaloni, Miguel Hernandez

AU - Nakakura, Eric

AU - VanBrocklin, Henry

AU - Slater, James

AU - Jivan, Salma

AU - Aparici, Carina Mari

AU - Yee, Judy

AU - Bergsland, Emily

PY - 2015/8/12

Y1 - 2015/8/12

N2 - Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.

AB - Objective: To evaluate a simultaneous PET/MRI approach to imaging patients with neuroendocrine tumor using a combination of 68Ga-DOTA-TOC as a PET contrast agent and gadoxetate disodium as a hepatobiliary MRI contrast agent. Materials and methods: Ten patients with neuroendocrine tumor with known or suspected hepatic disease were imaged using a 68Ga-DOTA-TOC PET/CT immediately followed by a 3.0T time-of-flight PET/MRI, using a combined whole body and liver specific imaging. The presence of lesions and DOTA-TOC avidity were assessed on CT, PET from PET/CT, diffusion weighted imaging, hepatobiliary phase imaging (HBP), and PET from PET/MRI. Maximum standardized uptake values (SUVmax) in hepatic lesions and nodal metastases were compared between PET/CT and PET/MRI, as were detection rates using each imaging approach. Results: A total of 101 hepatic lesions were identified, 47 of which were DOTA-TOC avid and able to be individually measured on both PET/CT and PET/MRI. HBP imaging had a higher sensitivity for detection of hepatic lesions compared to CT or PET (99% vs. 46% and 64%, respectively; p values <0.001). There was a strong correlation between SUVmax of liver lesions obtained with PET/CT compared to PET/MR imaging (Pearson’s correlation = 0.91). For nodal disease, CT had a higher sensitivity compared to whole body MRI (p = 0.015), although PET acquired from PET/MRI detected slightly more lesions compared to PET from PET/CT. Conclusions: A simultaneous PET/MRI using both 68Ga-DOTA-TOC and gadoxetate disodium was successful in whole body staging of patients with neuroendocrine tumor. HBP imaging had an increased detection rate for hepatic metastases.

KW - Ga-68 DOTA-TOC

KW - Hepatobiliary agents

KW - Neuroendocrine tumor

KW - PET/MRI

UR - http://www.scopus.com/inward/record.url?scp=84938985126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938985126&partnerID=8YFLogxK

U2 - 10.1007/s00261-015-0409-9

DO - 10.1007/s00261-015-0409-9

M3 - Article

C2 - 25820755

AN - SCOPUS:84938985126

VL - 40

SP - 1432

EP - 1440

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

IS - 6

ER -